new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)


Similar
Filing Names

Immunomedics Inc
Immunomedics Inc_20100114
Immunomedics Inc_20100121

Popular
Companies


Web
Adobe patents
Amazon patents
Apple patents
Ebay patents
Facebook patents
Google patents
IBM patents
Linkedin patents
Microsoft patents
Oracle patents
Red Hat patents
Yahoo patents

Food/Health
Adidas
Nike patents
Pfizer patents
Monsanto patents
Medtronic patents
Kraft patents

Transportation
Boeing patents
Tesla Motors patents

Telecom
Qualcomm patents
Motorola patents
Nokia patents
RIMM patents

Industrial/Electronics
AMD
Applied Materials
Seagate patents
General Electric
Caterpillar patents
Samsung
Wal-mart patents

  

Immunomedics Inc patents


      
Recent patent applications related to Immunomedics Inc. Immunomedics Inc is listed as an Agent/Assignee. Note: Immunomedics Inc may have other listings under different names/spellings. We're not affiliated with Immunomedics Inc, we're just tracking patents.

ARCHIVE: New 2015 2014 2013 2012 2011 2010 2009 | Company Directory "I" | Immunomedics Inc-related inventors




Search recent Press Releases: Immunomedics Inc-related press releases
Count Application # Date Immunomedics Inc patents (updated weekly) - BOOKMARK this page
12015023997408/27/15  new patent  Humanized rfb4 anti-cd22 antibody
22015022419208/13/15 Methods and compositions for treatment of human immunodeficiency virus infection with conjugated antibodies or antibody fragments
32015021699708/06/15 Dosages of immunoconjugates of antibodies and sn-38 for improved efficacy and decreased toxicity
42015021700608/06/15 Al-f-18-labeled, al-f-19-labeled and ga-68-labeled gastrin-releasing peptide receptor (grpr)-antagonists for imaging of prostate cancer
52015020231907/23/15 Dosages of immunoconjugates of antibodies and sn-38 for improved efficacy and decreased toxicity
62015020232007/23/15 Dosages of immunoconjugates of antibodies and sn-38 for improved efficacy and decreased toxicity
72015019665307/16/15 Dosages of immunoconjugates of antibodies and sn-38 for improved efficacy and decreased toxicity
82015019665407/16/15 Dosages of immunoconjugates of antibodies and sn-38 for improved efficacy and decreased toxicity
92015019666107/16/15 Dosages of immunoconjugates of antibodies and sn-38 for improved efficacy and decreased toxicity
102015019666207/16/15 Dosages of immunoconjugates of antibodies and sn-38 for improved efficacy and decreased toxicity
112015019666407/16/15 Dosages of immunoconjugates of antibodies and sn-38 for improved efficacy and decreased toxicity
122015019666507/16/15 Dosages of immunoconjugates of antibodies and sn-38 for improved efficacy and decreased toxicity
132015019666607/16/15 Dosages of immunoconjugates of antibodies and sn-38 for improved efficacy and decreased toxicity
142015018263307/02/15 Immunoconjugates with an intracellularly-cleavable linkage
152015018388007/02/15 Novel class of monospecific and bispecific humanized antibodies that target the insulin-like growth factor type i receptor (igf-1r)
162015017426906/25/15 Immunoconjugates with an intracellularly-cleavable linkage
172015017427006/25/15 Immunoconjugates with an intracellularly-cleavable linkage
182015016507506/18/15 Combining radioimmunotherapy and antibody-drug conjugates for improved cancer therapy
192015016507606/18/15 Anti-mucin antibodies for early detection and treatment of pancreatic cancer
202015016665906/18/15 Humanized l243 antibodies
212015016666906/18/15 Anti-cd74 immunoconjugates and methods of use
222015015096906/04/15 Chimeric and humanized anti-histone antibodies
232015013276805/14/15 Anti-pancreatic cancer antibodies
242015012538605/07/15 Humanized anti-ceacam5 antibody and uses thereof
252015011127904/23/15 Class i anti-cea antibodies and uses thereof
262015009445604/02/15 Anthracycline-antibody conjugates for cancer therapy
272015008648203/26/15 Dye conjugated peptides for fluorescent imaging
282015005743202/26/15 Methods and compositions for improved f-18 labeling of proteins, peptides and other molecules
292015003868602/05/15 Polymeric carriers of therapeutic agents and recognition moieties for antibody-based targeting of disease sites
302015001851601/15/15 Pro-drug form (p2pdox) of the highly potent 2-pyrrolinodoxorubicin conjugated to antibodies for targeted therapy of cancer
312014037717312/25/14 Anti-mucin antibodies for early detection and treatment of pancreatic cancer
322014037717712/25/14 Methods and compositions for improved f-18 labeling of proteins, peptides and other molecules
332014037728712/25/14 Anti-trop-2 antibody-drug conjugates and uses thereof
342014036992712/18/14 Camptothecin conjugates of anti-cd22 antibodies for treatment of b cell diseases
352014028686009/25/14 Immunoconjugates with an intracellularly-cleavable linkage
362014028686109/25/14 Rs7 antibodies
372014023420908/21/14 Chimeric and humanized anti-histone antibodies
382014022717808/14/14 Humanized anti-hla-dr antibodies
392014022717908/14/14 Anti-mucin antibodies for early detection and treatment of pancreatic cancer
402014022718008/14/14 Antibody-sn-38 immunoconjugates with a cl2a linker
412014022854108/14/14 Methods and compositions for improved f-18 labeling of proteins, peptides and other molecules
422014021991408/07/14 Dosages of immunoconjugates of antibodies and sn-38 for improved efficacy and decreased toxicity
432014021995608/07/14 Pro-drug form (p2pdox) of the highly potent 2-pyrrolinodoxorubicin conjugated to antibodies for targeted therapy of cancer
442014021242507/31/14 Therapeutic use of anti-cd22 antibodies for inducing trogocytosis
452014019335907/10/14 Ultrafiltration concentration of allotype selected antibodies for small-volume administration
462014017829406/26/14 Ultrafiltration concentration of allotype selected antibodies for small-volume administration
472014017006506/19/14 Methods and compositions for treatment of human immunodeficiency virus infection with conjugated antibodies or antibody fragments
482014015427306/05/14 Anthracycline-antibody conjugates for cancer therapy
492014014738205/29/14 Immunotherapy of b cell malignancies and autoimmune diseases using unconjugated antibodies and conjugated antibodies and antibody combinations and fusion proteins
502014014092405/22/14 Humanized l243 antibodies
512014012003505/01/14 Rs7 antibodies
522014011286404/24/14 Anti-mucin antibodies for early detection and treatment of pancreatic cancer
532014011286504/24/14 Anti-cd19 antibodies
542014010581904/17/14 In vivo copper-free click chemistry for delivery of therapeutic and/or diagnostic agents
552014009925804/10/14 Camptothecin-binding moiety conjugates
562014008683003/27/14 Novel class of monospecific and bispecific humanized antibodies that target the insulin-like growth factor type i receptor (igf-1r)
572014008683203/27/14 Delivery system for cytotoxic drugs by bispecific antibody pretargeting
582014007962903/20/14 Class i anti-cea antibodies and uses thereof
592014005806702/27/14 Immunoconjugates with an intracellularly-cleavable linkage
602014004463902/13/14 Antibody therapy
612014004464002/13/14 Combining radioimmunotherapy and antibody-drug conjugates for improved cancer therapy
622014003754302/06/14 Anti-pancreatic cancer antibodies
632014003826102/06/14 Compositions and methods of use of immunotoxins comprising ranpirnase (rap) show potent cytotoxic activity
642014003828402/06/14 Mammalian cell lines for increasing longevity and protein yield from a cell culture
652014001716801/16/14 Methods and compositions for improved f-18 labeling of proteins, peptides and other molecules
662014001719701/16/14 Anti-cd19 antibodies
672014000407801/02/14 Immunoconjugates with an intracellularly-cleavable linkage
682013031582111/28/13 Methods and compositions for improved f-18 labeling of proteins, peptides and other molecules
692013030917711/21/13 In vivo copper-free click chemistry for delivery of therapeutic and/or diagnostic agents
702013021656108/22/13 Immunoconjugates with an intracellularly-cleavable linkage
712013020935608/15/13 Combining radioimmunotherapy and antibody-drug conjugates for improved cancer therapy
722013021104408/15/13 Methods and compositions for improved f-18 labeling of proteins, peptides and other molecules
732013017749807/11/13 Methods and compositions for immunotherapy and detection of inflammatory and immune-dysregulatory disease, infectious disease, pathologic angiogenesis and cancer
742013017752607/11/13 Camptothecin conjugates of anti-cd22 antibodies for treatment of b cell diseases
752013017106407/04/13 Anti-cd74 immunoconjugates and methods of use
762013017106507/04/13 In vivo copper-free click chemistry for delivery of therapeutic and/or diagnostic agents
772013017117607/04/13 Anthracycline-antibody conjugates for cancer therapy
782013016421406/27/13 Antibody-based depletion of antigen-presenting cells and dendritic cells
792013016478306/27/13 Mammalian cell lines for increasing longevity and protein yield from a cell culture
802013015669106/20/13 Antibody therapy
812013014278706/06/13 Therapeutic use of anti-cd22 antibodies for inducing trogocytosis
822013014329606/06/13 Delivery system for cytotoxic drugs by bispecific antibody pretargeting
832013012191305/16/13 Anti-cd19 antibodies
842013012347305/16/13 Bispecific antibody targeting a complement factor or complement regulatory protein
852013009503404/18/13 Anti-cd74 immunoconjugates and methods
862013009045804/11/13 Immunoconjugates with an intracellularly-cleavable linkage
872013007818203/28/13 Structural variants of antibodies for improved therapeutic characteristics
882013007826303/28/13 Anti-hla-dr antibodies suppress allogeneic and xenogeneic immune responses to organ transplants
892013007132003/21/13 Immunotherapy of autoimmune disorders using antibodies which target b-cells
902013007140603/21/13 Methods and compositions for treatment of human immunodeficiency virus infection with conjugated antibodies or antibody fragments
912013007265903/21/13 Polymeric carriers of therapeutic agents and recognition moieties for antibody-based targeting of disease sites
922013003986102/14/13 Dye conjugated peptides for fluorescent imaging
932013003449202/07/13 Class i anti-cea antibodies and uses thereof
942012032856412/27/12 Camptothecin-binding moiety conjugates
952012032863412/27/12 Immunoconjugates with an intracellularly-cleavable linkage
962012032155312/20/12 Ultrafiltration concentration of allotype selected antibodies for small-volume administration
972012028217811/08/12 Methods and compositions for improved f-18 labeling of proteins, peptides and other molecules
982012027610011/01/12 Compositions and methods of use of immunotoxins comprising ranpirnase (rap) show potent cytotoxic activity
992012023095309/13/12 Methods and compositions for immunotherapy and detection of inflammatory and immune-dysregulatory disease, infectious disease, pathologic angiogenesis and cancer
1002012021496908/23/12 Methods and compositions for f-18 labeling of proteins, peptides and other molecules
1012012019632608/02/12 Mammalian cell lines for increasing longevity and protein yield from a cell culture
1022012018954207/26/12 Anti-cd19 antibodies
1032012018347207/19/12 Immunotherapy of b-cell malignancies using anti-cd22 antibodies
1042012018355007/19/12 Therapeutic using a bispecific antibody
1052012014908506/14/12 Fusion proteins containing recombinant cytotoxic rnases
1062012014137206/07/12 Rs7 antibodies
1072012014137506/07/12 Anti-mucin antibodies for early detection and treatment of pancreatic cancer
1082012013492005/31/12 Methods and compositions for improved f-18 labeling of proteins, peptides and other molecules
1092012011455605/10/12 Immunotherapy of autoimmune disorders using antibodies which target b-cells
1102012010723505/03/12 Alpha-fetoprotein immu31 antibodies and fusion proteins and methods of use thereof
1112012008829904/12/12 Mammalian cell lines for increasing longevity and protein yield from a cell culture
1122012008261704/05/12 Immunoconjugates with an intracellularly-cleavable linkage
1132012007672703/29/12 In vivo copper-free click chemistry for delivery of therapeutic and/or diagnostic agents
1142012006399303/15/12 Therapeutic and diagnostic conjugates for use with multispecific antibodies
1152012003979702/16/12 Antibody therapy
1162012004043102/16/12 Polymeric carriers of therapeutic agents and recognition moieties for antibody-based targeting of disease sites
1172012003418502/09/12 Anti-cd20 antibodies and fusion proteins therof and methods of use
1182011031153112/22/11 Immunotherapy of autoimmune disorders using antibodies which target b-cells
1192011030563112/15/11 Camptothecin conjugates of anti-cd22 antibodies for treatment of b cell diseases
1202011030006612/08/11 Combination therapy with anti-cd74 antibodies provides enhanced toxicity to malignancies, autoimmune disease and other diseases
1212011029351312/01/11 Immunoconjugates with an intracellularly-cleavable linkage
1222011028691811/24/11 Immunotherapy of autoimmune disorders using antibodies which target b-cells
1232011028080111/17/11 Methods and compositions for f-18 labeling of proteins, peptides and other molecules
1242011027470411/10/11 Compositions and methods of use of immunotoxins comprising ranpirnase (rap) show potent cytotoxic activity
1252011025605310/20/11 Multiple signaling pathways induced by hexavalent, monospecific and bispecific antibodies for enhanced toxicity to b-cell lymphomas and other diseases
1262011024384110/06/11 Antibody-based depletion of antigen-presenting cells and dendritic cells
1272011024454610/06/11 Internalizing anti-cd74 antibodies and methods of use
1282011023630409/29/11 Structural variants of antibodies for improved therapeutic characteristics
1292011023640409/29/11 Methods for protein expression in mammalian cells in serum-free medium
1302011022940709/22/11 Alpha-fetoprotein immu31 antibodies and fusion proteins and methods of use thereof
1312011022364509/15/11 Multivalent carriers of bi-specific antibodies
1322011019502308/11/11 Internalizing anti-cd74 antibodies and methods of use
1332011018908508/04/11 Antibody therapy
1342011018926808/04/11 Inhibition of placenta growth factor (plgf) mediated metastasis and/or angiogenesis
1352011017112607/14/11 Enhanced cytotoxicity of anti-cd74 and anti-hla-dr antibodies with interferon-gamma
1362011016507207/07/11 Detection of early-stage pancreatic adenocarcinoma
1372011016507307/07/11 Immunotherapy of b-cell malignancies using anti-cd22 antibodies
1382011011701005/19/11 Methods and compositions for administering therapeutic and diagnostic agents
1392011011710505/19/11 Method of treating immune disease using b-cell antibodies
1402011011085405/12/11 Methods and compositions for improved f-18 labeling of proteins, peptides and other molecules
1412011007623303/31/11 Delivery system for cytotoxic drugs by bispecific antibody pretargeting
1422011007015503/24/11 Anti-cd74 immunoconjugates and methods
1432011007015603/24/11 Combining radioimmunotherapy and antibody-drug conjugates for improved cancer therapy
1442011006465303/17/11 Class i anti-cea antibodies and uses thereof
1452011005248903/03/11 Anti-cd19 antibodies
1462010031116212/09/10 Mammalian cell lines for increasing longevity and protein yield from a cell culture
1472010028490611/11/10 Internalizing anti-cd74 antibodies and methods of use
1482010027263610/28/10 Anti-cd74 immunoconjugates and methods of use
1492010026649610/21/10 Anti-cd74 immunoconjugates and methods of use
1502010026649710/21/10 Internalizing anti-cd74 antibodies and methods of use
1512010023377909/16/10 Polymeric carriers of therapeutic agents and recognition moieties for antibody-based targeting of disease sites
1522010022688409/09/10 Novel class of monospecific and bispecific humanized antibodies that target the insulin-like growth factor type i receptor (igf-1r)
1532010022117509/02/10 Antibody therapy
1542010022117709/02/10 Rs7 antibodies
1552010021666208/26/10 Inhibition of placenta growth factor (plgf) mediated metastasis and/or angiogenesis
1562010020296108/12/10 D-amino acid peptides
1572010019626608/05/10 Humanized anti-hla-dr antibodies
1582010019626708/05/10 Humanized l243 antibodies
1592010019698908/05/10 Alpha-fetoprotein immu31 antibodies and fusion proteins and methods of use thereof
1602010018964107/29/10 Novel strategies for improved cancer vaccines
1612010015880206/24/10 Chimeric, human and humanized anti-csap monoclonal antibodies
1622010015880306/24/10 Production and use of novel peptide-based agents for use with bi-specific antibodies
1632010013662606/03/10 Production and use of novel peptide-based agents for use with bi-specific antibodies
1642010010458904/29/10 Immunoconjugates with an intracellularly-cleavable linkage
1652010007484003/25/10 Anthracycline-antibody conjugates for cancer therapy
1662010006813603/18/10 Anti-cd19 antibodies
1672010004054102/18/10 Structural variants of antibodies for improved therapeutic characteristics
1682010003473802/11/10 Structural variants of antibodies for improved therapeutic characteristics
1692010001504601/21/10 Camptothecin-binding moiety conjugates
1702010001504801/21/10 Internalizing anti-cd74 antibodies and methods of use
1712010000885501/14/10 Production and use of novel peptide-based agents with bispecific antibodies
1722010000885801/14/10 Methods and compositions for improved f-18 labeling of proteins, peptides and other molecules
1732009030458012/10/09 Anti-pancreatic cancer antibodies
1742009029903312/03/09 Methods and compositions for f-18 labeling of proteins, peptides and other molecules
1752009029109311/26/09 Immunoconjugates with an intracellularly-cleavable linkage
1762009028575211/19/09 Immunotherapy of b cell malignancies and autoimmune diseases using unconjugated antibodies and conjugated antibodies and antibody combinations and fusion proteins
1772009027464911/05/09 Bispecific antibody point mutations for enhancing rate of clearance
1782009025273110/08/09 Multivalent carriers of bi-specific antibodies
1792009025317910/08/09 Mammalian cell lines for increasing longevity and protein yield from a cell culture
1802009024613010/01/09 Methods and compositions for f-18 labeling of proteins, peptides and other molecules
1812009024613110/01/09 Production and use of novel peptide-based agents for use with bi-specific antibodies
1822009024621410/01/09 Fusion proteins containing recombinant cytotoxic rnases
1832009023875709/24/09 Methods and compositions for administering therapeutic and diagnostic agents
1842009024003709/24/09 Humanized antibodies and methods of humanizing antibodies
1852009018597407/23/09 Chimeric, human and humanized anti-granulocyte antibodies and methods of use
1862009015516606/18/09 Methods and compositions for f-18 labeling of proteins, peptides and other molecules
1872009015525306/18/09 Anti-cd20 antibodies and fusion proteins therof and methods of use
1882009011114304/30/09 Methods and compositions for mammalian cell lines for transfection and protein expression in serum-free medium
1892009009259804/09/09 Antibody therapy
1902010001504801/21/10 Internalizing anti-cd74 antibodies and methods of use
1912010000885801/14/10 Methods and compositions for improved f-18 labeling of proteins, peptides and other molecules



ARCHIVE: New 2015 2014 2013 2012 2011 2010 2009



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Immunomedics Inc in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Immunomedics Inc with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com

###

     SHARE